Halozyme Therapeutics, Inc. (HALO)
125.63
+1.09
(+0.88%)
USD |
NASDAQ |
Oct 23, 16:00
125.59
-0.04
(-0.03%)
After-Hours: 20:00
Halozyme Therapeutics Price to Book Value : 99.81 for Oct. 23, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 23, 2026 | 99.81 |
| October 22, 2026 | 98.94 |
| October 21, 2026 | 99.17 |
| October 20, 2026 | 98.81 |
| October 19, 2026 | 97.32 |
| October 16, 2026 | 96.80 |
| October 15, 2026 | 96.54 |
| October 14, 2026 | 92.81 |
| October 13, 2026 | 87.09 |
| October 12, 2026 | 88.25 |
| October 09, 2026 | 87.73 |
| October 08, 2026 | 87.27 |
| October 07, 2026 | 88.02 |
| October 06, 2026 | 87.17 |
| October 05, 2026 | 86.05 |
| October 02, 2026 | 87.28 |
| October 01, 2026 | 84.96 |
| September 30, 2026 | 87.71 |
| September 29, 2026 | 88.63 |
| September 28, 2026 | 89.69 |
| September 25, 2026 | 90.49 |
| September 24, 2026 | 91.54 |
| September 23, 2026 | 89.33 |
| September 22, 2026 | 91.47 |
| September 21, 2026 | 88.54 |
| Date | Value |
|---|---|
| September 18, 2026 | 89.34 |
| September 17, 2026 | 87.14 |
| September 16, 2026 | 86.15 |
| September 15, 2026 | 84.41 |
| September 14, 2026 | 85.76 |
| September 11, 2026 | 85.17 |
| September 10, 2026 | 85.01 |
| September 09, 2026 | 85.32 |
| September 08, 2026 | 86.05 |
| September 04, 2026 | 87.54 |
| September 03, 2026 | 88.00 |
| September 02, 2026 | 87.12 |
| September 01, 2026 | 85.58 |
| August 31, 2026 | 84.60 |
| August 28, 2026 | 83.70 |
| August 27, 2026 | 84.95 |
| August 26, 2026 | 85.06 |
| August 25, 2026 | 86.85 |
| August 24, 2026 | 86.31 |
| August 21, 2026 | 85.94 |
| August 20, 2026 | 84.31 |
| August 19, 2026 | 85.50 |
| August 18, 2026 | 83.33 |
| August 17, 2026 | 81.83 |
| August 14, 2026 | 78.38 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| AVITA Medical, Inc. | -- |
| Iovance Biotherapeutics, Inc. | 8.671 |
| Merck & Co., Inc. | 8.552 |
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.32 |
Price to Book Value Related Metrics
| PE Ratio | 37.54 |
| PS Ratio | 9.138 |
| Price to Free Cash Flow | 18.86 |
| Price | 125.63 |
| Earnings Yield | 2.66% |
| Market Cap | 14.33B |
| Operating PE Ratio | 16.10 |
| Normalized PE Ratio | 23.07 |